Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Oesophageal Cancer

Presenters

Chia-Lun Chang

Citation

Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422

Authors

C. Chang, S. Wu

Author affiliations

  • Director & Attending Physician, Department Of Radiation Oncology, Taipei Medical, Taipei Medical University - Municipal Wan Fang Hospital, 116 - Taipei/TW

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 152P

Background

Till date, intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) and CCRT with standard fractionation three-Dimensional Conformal Radiation Therapy (3D-CRT) have not been compared. In the current study, the outcomes of IMRT-based concurrent chemoradiotherapy (CCRT) and those of 3D-CRT-based CCRT were compared in patients with thoracic esophageal squamous cell carcinoma (TESCC).

Methods

We enrolled 2062 patients with TESCC who had received CCRT and categorized them into two groups based on their treatment modality: group 1 (3D-CRT-based CCRT) and group 2 (IMRT-based CCRT).

Results

The multivariate Cox regression analysis indicated that advanced stages (≥IIIA) of the American Joint Committee on Cancer and 3D-CRT were significant independent predictors of poor outcome in patients with TESCC who received definitive CCRT. Moreover, receiving IMRT-based CCRT (adjusted HR [aHR]: 0.88; 95% confidence interval [CI]: 0.78-0.98) was a significant independent prognostic factor for overall survival (P = .0223). The aHRs (95% CIs) for overall mortality at early (IA-IIB) and advanced clinical stages were 0.91 (0.67-1.25, P = .5746) and 0.88 (0.77-0.99, P = .0368), respectively, in group 2.

Conclusions

IMRT-based CCRT resulted in higher survival rates in the patients with advanced clinical stages IIIA-IIIC TESCC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.